In the study, BSI-201demonstrated that treatment with the drug in combination with gemcitabine/carboplatin results in a improvement in overall survival and a high rate of clinical response in women with metastatic triple negative breast cancer (mTNBC).
Lead investigator of the study Joyce O’Shaughnessy said that those results confirm that more than half of the patients treated with BSI-201 (iniparib) had substantial decrease in their tumor burden and they lived longer than women getting chemotherapy alone.
"Iniparib appears to enhance the ability of chemotherapy to kill cancer cells without increasing the severity of adverse events," Shaughnessy said.
Sanofi-aventis Global Oncology senior vice president Debasish Roychowdhury said that BSI 201
continues to demonstrate potential as a new treatment option for women with metastatic triple negative breast cancer.
Iniparib has received fast track designation from the US Food and Drug Administration for mTNBC.